Healthcare [ 13/13 ] | Drug Manufacturers - Specialty & Generic [ 77/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 9, 23 | -0.27 Increased by +49.06% | -1.84 Increased by +85.33% |
| Aug 9, 23 | -2.15 Increased by +20.66% | -7 Increased by +69.29% |
| May 11, 23 | -5.91 Decreased by -56.35% | -7.5 Increased by +21.2% |
| Mar 22, 23 | -5 Increased by +37.5% | -11.5 Increased by +56.52% |
| Nov 7, 22 | -0.53 Increased by +92.64% | -0.44 Decreased by -20.45% |
| Aug 11, 22 | -2.71 Increased by +66.13% | -3.7 Increased by +26.76% |
| May 12, 22 | -3.78 Increased by +52.75% | -6 Increased by +37% |
| Mar 30, 22 | -8 Increased by 0% | -6 Decreased by -33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 6.66 M Increased by +121.92% | -799 K Increased by +96.38% | Decreased by -11.99% Increased by +98.37% |
| Jun 30, 23 | 5.5 M Increased by +158.84% | -3.81 M Increased by +70.79% | Decreased by -69.22% Increased by +88.72% |
| Mar 31, 23 | 3.81 M Increased by +116.52% | -3.61 M Increased by +69.33% | Decreased by -94.68% Increased by +85.83% |
| Dec 31, 22 | 4 M Increased by +163.94% | -13.28 M Increased by +43.15% | Decreased by -332.31% Increased by +78.46% |
| Sep 30, 22 | 3 M Increased by +133.26% | -22.05 M Decreased by -31.46% | Decreased by -734.48% Increased by +43.64% |
| Jun 30, 22 | 2.13 M Increased by +79.41% | -13.04 M Increased by +26.06% | Decreased by -613.36% Increased by +58.79% |
| Mar 31, 22 | 1.76 M Increased by +1.42 K% | -11.77 M Increased by +31.29% | Decreased by -668.31% Increased by +95.47% |
| Dec 31, 21 | 1.51 M Increased by +102.14% | -23.36 M Decreased by -32.57% | Decreased by -1.54 K% Increased by +34.42% |
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.